ARDX vs. DNA
ARDX (Ardelyx, Inc.) and DNA (Ginkgo Bioworks Holdings, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, ARDX returned -4.70%/yr vs -53.32%/yr for DNA. At a 0.29 correlation, their price movements are largely independent.
Performance
ARDX vs. DNA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ARDX achieves a 6.00% return, which is significantly lower than DNA's 6.62% return.
ARDX
- 1D
- -2.98%
- 1M
- 1.15%
- YTD
- 6.00%
- 6M
- 6.55%
- 1Y
- 70.25%
- 3Y*
- 19.74%
- 5Y*
- -4.70%
- 10Y*
- -2.60%
DNA
- 1D
- -1.99%
- 1M
- 5.35%
- YTD
- 6.62%
- 6M
- 1.03%
- 1Y
- 3.87%
- 3Y*
- -49.30%
- 5Y*
- -53.32%
- 10Y*
- —
ARDX vs. DNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
ARDX Ardelyx, Inc. | 6.00% | 14.99% | -18.23% | 117.54% | 159.09% | -87.34% |
DNA Ginkgo Bioworks Holdings, Inc. | 6.62% | -15.38% | -85.47% | 0.00% | -79.66% | -21.68% |
Correlation
The correlation between ARDX and DNA is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.24 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.26 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since Apr 19, 2021 | 0.29 |
Fundamentals
ARDX:
$1.52B
DNA:
$527.73M
ARDX:
-$0.24
DNA:
-$5.40
ARDX:
3.51
DNA:
4.10
ARDX:
10.22
DNA:
1.19
ARDX:
$427.68M
DNA:
$121.84M
ARDX:
$395.63M
DNA:
$99.27M
ARDX:
-$28.55M
DNA:
-$218.90M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ARDX vs. DNA — Risk / Return Rank
ARDX
DNA
ARDX vs. DNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ardelyx, Inc. (ARDX) and Ginkgo Bioworks Holdings, Inc. (DNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ARDX | DNA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.11 | ||
| Sortino ratioReturn per unit of downside risk | +1.36 | ||
| Omega ratioGain probability vs. loss probability | 1.26 | 1.10 | +0.16 |
| Calmar ratioReturn relative to maximum drawdown | 2.11 | 0.06 | +2.05 |
| Martin ratioReturn relative to average drawdown | 4.07 | 0.10 | +3.97 |
Loading charts...
Drawdowns
ARDX vs. DNA - Drawdown Comparison
The maximum ARDX drawdown since its inception was -98.45%, roughly equal to the maximum DNA drawdown of -99.10%. Use the drawdown chart below to compare losses from any high point for ARDX and DNA.
Loading charts...
Drawdown Indicators
| ARDX | DNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.45% | -99.10% | +0.65% |
Max Drawdown (1Y)Largest decline over 1 year | -33.54% | -66.05% | +32.51% |
Max Drawdown (3Y)Largest decline over 3 years | -66.32% | -94.72% | +28.40% |
Max Drawdown (5Y)Largest decline over 5 years | -93.76% | -99.10% | +5.34% |
Max Drawdown (10Y)Largest decline over 10 years | -96.82% | — | — |
Current DrawdownCurrent decline from peak | -81.21% | -98.52% | +17.31% |
Average DrawdownAverage peak-to-trough decline | -77.37% | -79.96% | +2.59% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.31% | 39.73% | -22.42% |
Volatility
ARDX vs. DNA - Volatility Comparison
The current volatility for Ardelyx, Inc. (ARDX) is 12.95%, while Ginkgo Bioworks Holdings, Inc. (DNA) has a volatility of 19.57%. This indicates that ARDX experiences smaller price fluctuations and is considered to be less risky than DNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ARDX | DNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.95% | 19.57% | -6.62% |
Volatility (6M)Calculated over the trailing 6-month period | 46.39% | 70.77% | -24.38% |
Volatility (1Y)Calculated over the trailing 1-year period | 61.42% | 97.62% | -36.20% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 89.49% | 97.96% | -8.47% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 83.99% | 96.20% | -12.21% |
Dividends
ARDX vs. DNA - Dividend Comparison
Neither ARDX nor DNA has paid dividends to shareholders.
Financials
ARDX vs. DNA - Financials Comparison
This section allows you to compare key financial metrics between Ardelyx, Inc. and Ginkgo Bioworks Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ARDX and DNA have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
DNA has higher volatility (19.57%) compared to ARDX (12.95%). In terms of maximum drawdown, ARDX dropped -98.45% vs DNA's -99.10%.
ARDX currently has the higher Sharpe Ratio (1.15 vs 0.04), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ARDX and DNA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer